8-K current report · filed Aug 5, 2026

Exelixis Inc (EXEL) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1EXEL overview

Short answer

Exelixis Inc (EXEL) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended July 3, 2026.

Exelixis Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended July 3, 2026
  • Corporate update accompanying Exelixis’ quarterly results
  • Full financial figures and guidance in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $628.7M, up from $568.3M, driven by cabozantinib product revenue of $573.0M
  • GAAP diluted EPS $0.82, up from $0.65, with buybacks reducing diluted shares to 259.7M from 284.4M
  • FY2026 revenue guidance reduced to $2.500B-$2.550B from $2.525B-$2.625B
  • FDA decision on zanzalintinib CRC application targeted for December 3, 2026, excluding potential launch revenue from guidance
  • $750M additional repurchase authorization, following $2.9B of cumulative buybacks and 93.3M shares retired

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Exelixis Inc 8-K filings

Get the next EXEL 8-K as it lands

Follow EXEL for push alerts, or ask the research agent what this filing means.